Actively Recruiting
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
Led by Sun Yat-sen University · Updated on 2021-03-02
320
Participants Needed
1
Research Sites
305 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although resection was recommend for early stage (BCLC A stage) patients according to the BCLC (Barcelona clinical liver cancer) system, increasing studies suggested that preoperative transarterial therapy may decrease the recurrence risk for those with high-risk factors. However, the clinical value is still undertermined. Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for unresectable HCC. Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate. Whether TACE-HAIC would improve survival for BCLC A stage patients with high-risk factors is need to further to study. A randomized clinical trial compared neo-TACE-HAIC with surgery versus surgery alone is aimed to answer this question.
CONDITIONS
Official Title
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years
- BCLC A stage hepatocellular carcinoma with high recurrence risk factors
- Resectable primary hepatocellular carcinoma
- Child-Pugh A or B liver function with a score of 7 or less
- Residual liver volume greater than 30%
You will not qualify if you...
- Unresectable hepatocellular carcinoma
- Pregnant or breastfeeding women
- Presence of other malignant cancers
- Previous anti-HCC therapy before this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
J
Jiliang Qiu
CONTACT
X
Xuzhi Pan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here